Remedy for Systemic Inflammatory Response Syndrome (SIRS)

Injury results in release of cytoplasmic ATP, which is sensed by monocytes/macrophages via ATP receptor P2X7. This swiftly induces inflammasome activation, caspase-1-dependent cleavage and release of interleukin-1ß (IL-1ß), IL-18 and HMGB1. Excessive systemic IL-1ß release is the first stage of a reaction chain causing SIRS and high patient mortality.

IL-1ß is involved in host defense against infections. Pathogen-induced inflammasome activation, however, typically involve ATP-independent pathways. Hence, a-1-antitrypsin, SLPI, CRP, and DPPC inhibit injury induced inflammation but do not inhibit clearance of pathogens.

Scope of application: SIRS, Major surgery, Trauma, Extracorporeal circulation (e.g. cardiopulmonary bypass, ECMO), Chronic inflammation, Lung injury

SIRS-related multi organ dysfunction (MODS) and acute lung injury (ALI) are among the leading causes of death worldwide. The proposed remedies have the potential to become affordable life-saving medicaments for numerous indications.

Further information: PDF

TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12

Contact
Dr. Peter Stumpf

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.